Don’t Trade in the Dark—Get Your Pre-Market Report Every Day.Join Now
Pharmaceuticals & Biotechnology | Small Cap
Health Score : 4.39Lasa Supergenerics Ltd, operating in the Healthcare Services sector, presents a mixed financial picture. The company demonstrates strengths in solvency, driven by a solid equity base. However, liquidity is a significant concern, with all ratios indicating poor short-term financial health. Growth metrics are volatile, with high operating profit and EPS growth offset by declines in asset and revenue growth. Coverage ratios are weak, reflecting challenges in meeting interest obligations. Profitability is also a concern, with low margins and returns. While the company shows positive trends in specific growth areas, the overall financial health is hampered by liquidity and profitability issues, suggesting potential risks for investors.
Health Score : 4.39Lasa Supergenerics Ltd, operating in the Healthcare Services sector, presents a mixed financial picture. The company demonstrates strengths in solvency, driven by a solid equity base. However, liquidity is a significant concern, with all ratios indicating poor short-term financial health. Growth metrics are volatile, with high operating profit and EPS growth offset by declines in asset and revenue growth. Coverage ratios are weak, reflecting challenges in meeting interest obligations. Profitability is also a concern, with low margins and returns. While the company shows positive trends in specific growth areas, the overall financial health is hampered by liquidity and profitability issues, suggesting potential risks for investors.
Overall Valuation Score
Markets Depth NSE
Buy Orders
Bid
Quantity
Orders
No buy depth
Total
0
0
Sell Orders
Ask
Quantity
Orders
No sell depth
Total
0
0
Markets Today NSE
High
0.00
Low
0.00
Open
0.00
Close
0.00
Prev Close
0.00
Avg Price
0.00
Volume
0
Last Traded Quantity
0
Last Traded Time
N/A
Price Movement Indicator
Today's Low: 0.00
Today's High: 0.00
P/E RATIO (TTM)
-1.16
Industry Median
23.93
Small Cap Median
23.93
P/E RATIO
-2.61
P/B RATIO
0.46
Industry Median
2.53
Small Cap Median
2.53
P/S RATIO
0.27
Industry Median
1.35
Small Cap Median
1.35
Others
PEG RATIO
0.10
EV/EBITDA RATIO
-9.41
The Calculations Shown Above Are Based on the Last Traded Price (LTP) of ₹7.7 as on Jun 15, 2026.
Growth Score : 5.20The company's growth ratios show significant volatility. While operating profit and EPS growth rates are strong, revenue, asset, and net income growth rates are weak. This suggests that the company's profitability improvements may not be sustainable without broader growth across all areas. The healthcare industry's dynamic nature requires consistent growth in revenue and assets to maintain a competitive edge.
Revenue Growth RatePoorOperating Profit Growth RateExcellentEarnings Per Share (EPS) GrowthExcellentAsset Growth RatePoorNet Income Growth RatePoor| Growth Ratios | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Revenue Growth Rate | -31.84 | -5.11 | -20 | 36.54 | -82.39 |
| Operating Profit Growth Rate | -65.96 | -137.5 | 133.33 | 200 | -216.67 |
| Earnings Per Share (EPS) Growth | -123.39 | -488.55 | 43.71 | 32.03 | -130.51 |
| Asset Growth Rate | 0.48 | -21.53 | -7.93 | -32.45 | -35.29 |
| Net Income Growth Rate | -121.74 | -680 | 43.59 | 31.82 | -126.67 |
Revenue Growth Rate
Operating Profit Growth Rate
Earnings Per Share (EPS) Growth
Asset Growth Rate
Net Income Growth Rate
Peer Comparison empowers investors to evaluate a company against its industry peers using key financial metrics like P/E ratio, EPS, and profit margins. It helps identify whether a company is overvalued, undervalued, or performing in line with competitors. Investors can use this data to spot opportunities, assess risks, and make informed decisions. This contextual view adds depth beyond standalone company analysis.
| NO | Company Name | Health Score | P/E Ratio | Valuation | OPM | EPS | Latest Profit & Loss |
|---|---|---|---|---|---|---|---|
| 1 | MEDIORG | 6.30 | -7.77 | Neutral | -3.75 | -2.50 | -4.02 |
| 2 | MONOPHARMA | 6.16 | 42.75 | Neutral | 4.00 | 0.20 | N/A |
| 3 | JFLLIFE | 6.07 | 10.88 | Neutral | 12.00 | 1.94 | 6.00 |
| 4 | WALPAR | 5.29 | 9.89 | Neutral | 6.66 | 2.09 | 3.00 |
| 5 | MANGALAM | 4.50 | -1.06 | Neutral | -15.00 | -27.68 | -44.00 |
| 6 | LASA | 4.39 | -2.61 | Highly Undervalued | -7.00 | -6.80 | -34.00 |
0 Credits RemainingUnlock Deep Technical Insights in Seconds Only with Dhanarthi AI
Overall Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Strong Bearish
Market Sentiment
Analysis Driven By 26 Technical Indicators From The 1 Hour Timeframe
Trend Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Strong Bearish
Momentum Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bearish
Volatility Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
Volume Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
Analyzing moving average trends and crossovers. Green/Red badges indicate if the current condition passes or fails.
Comparing stock price performance (normalized) against benchmark indices over time.
Recent daily trading volume represented as a bar chart, alongside historical averages.
Current closing price relative to the 52-week highest and lowest prices.
No Stock Reports Available at This Moment.
No Stock News Available at This Moment.
Lasa Supergenerics Ltd. is an Indian pharmaceutical company engaged in the manufacturing of Active Pharmaceutical Ingredients (APIs) and advanced intermediates. It specializes in veterinary APIs, particularly anthelmintic drugs, and also produces various human APIs. The company serves both domestic and international markets, focusing on R&D-driven product development and cost-effective manufacturing.
P/E Ratio (TTM): Price to Earnings ratio shows how much an investor pays for every rupee of the company's earnings. Lasa Supergenerics Ltd's P/E ratio (TTM) is -1.16, compared to the industry median of 23.93 and large cap median of 23.93.
P/B Ratio: Price to Book ratio compares a company's market price to its book value per share. Lasa Supergenerics Ltd's P/B ratio is 0.46, compared to the industry median of 2.53 and large cap median of 2.53.
P/S Ratio: Price to Sales ratio compares a company's market value to its total revenue. Lasa Supergenerics Ltd's P/S ratio is 0.27, compared to the industry median of 1.35 and large cap median of 1.35.
PEG Ratio: PEG ratio adjusts the P/E ratio for expected earnings growth. Lasa Supergenerics Ltd's PEG ratio is 0.10.
EV/EBITDA Ratio: This ratio compares a company's enterprise value to its earnings before interest, tax, depreciation, and amortization. Lasa Supergenerics Ltd's EV/EBITDA ratio is -9.41.
Return on Equity (ROE): ROE measures how much profit a company generates from shareholders' invested capital. Lasa Supergenerics Ltd's ROE is -68%.
Return on Assets (ROA): ROA measures how efficiently a company converts its assets into net profit. Lasa Supergenerics Ltd's ROA is -10.61%.
Return on Capital Employed (ROCE): ROCE measures how efficiently a company generates profit from all the capital it employs. Lasa Supergenerics Ltd's ROCE is -18%.
Operating Margin: Operating margin shows what percentage of revenue remains after covering operating expenses. Lasa Supergenerics Ltd's operating margin is -28%.
Net Margin: Net margin shows what percentage of revenue converts into final net profit. Lasa Supergenerics Ltd's net margin is -136%.
Current Ratio: The current ratio measures a company's ability to pay short-term liabilities using short-term assets. Lasa Supergenerics Ltd's current ratio is 0.66.
Debt to Equity Ratio: This ratio shows the proportion of debt a company uses relative to shareholders' equity. Lasa Supergenerics Ltd's debt-to-equity ratio is 0.
Interest Coverage Ratio: This ratio shows how easily a company can pay interest on its outstanding debt from its operating earnings. Lasa Supergenerics Ltd's interest coverage ratio is -5.33.
Dividend Per Share (DPS): DPS shows the total dividend paid per share in the latest financial year. Lasa Supergenerics Ltd's DPS is ₹0.
Earnings Per Share (EPS): EPS shows how much profit is allocated to each outstanding share. Lasa Supergenerics Ltd's EPS is -130.51.
(Source line: "Ratios as of 15 Jun 2026, based on last traded price of ₹7.70. Data sourced from BSE/NSE Exchange Filings & Public Terminal Data.")
Founded: 2016 (as a subsidiary of Omkar Speciality Chemicals Ltd.)
Headquarters: Mahad, Maharashtra
Core Offerings: Veterinary APIs, Human APIs, Pharma Intermediates, Anthelmintic Drugs
Stock Listing: NSE (LASA), BSE (540702)
Promoter: Dr. Omkar Herlekar & Family
Lasa Supergenerics Ltd. was incorporated in 2016 as a wholly-owned subsidiary of Omkar Speciality Chemicals Ltd. It was subsequently demerged from Omkar Speciality Chemicals Ltd. in 2017 to create a focused entity for the Active Pharmaceutical Ingredients (API) business. The company was listed on Indian stock exchanges in 2017, marking its independence and direct market presence in the pharmaceutical sector.
| Segment Name | Revenue % | EBITDA |
|---|---|---|
| Active Pharmaceutical Ingredients (APIs) | 100% | Consolidated |
Active Pharmaceutical Ingredients (APIs): Manufactures a diverse range of APIs and advanced intermediates, with a strong focus on veterinary APIs, especially for anthelmintic applications.
Key Therapeutic Areas: Specializes in producing drugs for de-worming (anthelmintics) for both animal and human health, along with other niche APIs.
Manufacturing Facilities: Operates state-of-the-art manufacturing plants in Raigad, Maharashtra, equipped for various chemical synthesis processes.
Dr. Omkar Herlekar - Chairman & Managing Director. He holds a Ph.D. in Chemistry and is the visionary force behind the company's research, development, and operational strategies.
No major subsidiaries reported.
The company was formed through a demerger from Omkar Speciality Chemicals Ltd. in 2017. Subsequently, it undertook a Rights Issue in 2021 to raise capital for expansion and working capital needs.
The Lasa Supergenerics Ltd share price today is ₹7.70 on NSE (LASA), as of 13 Sept 2026.
As of 15 Jun 2026, Lasa Supergenerics Ltd share price is ₹7.70, with previous close ₹7.70. Today's range is ₹7.70 to ₹7.70. The 52-week range is ₹7.70 to ₹7.70.
As of today, Lasa Supergenerics Ltd's market cap is ₹38.58 crore (Small Cap).
Lasa Supergenerics Ltd's current P/E ratio is -1.16, compared to the REAL ESTATE sector average of 29.50.
Lasa Supergenerics Ltd's current P/B ratio is 0.46.
Lasa Supergenerics Ltd's current dividend yield is N/A. Last dividend of ₹0.00 per share was declared on N/A.
Lasa Supergenerics Ltd's EPS (TTM) is ₹-130.51.
Lasa Supergenerics Ltd. is an Indian pharmaceutical company engaged in the manufacturing of Active Pharmaceutical Ingredients (APIs) and advanced intermediates. It specializes in veterinary APIs, particularly anthelmintic drugs, and also produces various human APIs. The company serves both domestic and international markets, focusing on R&D-driven product development and cost-effective manufacturing.
Lasa Supergenerics Ltd is promoted by Dr. Omkar Herlekar & Family, holding 53.65% as of 15 Jun 2026.
Lasa Supergenerics Ltd is listed on NSE (LASA) and BSE (540702). Its next quarterly results are expected on August 2024 (Q1 FY25).
Cash Earnings Per Share (Cash EPS)
Strategic & Operational Indicators